The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), and his wife, Olena Wright, have purchased a total of 434,704 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 5.76p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,532,109 Ordinary Shares, representing approximately 0.35 per cent of the Company's issued share capital.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Hemogenyx Chairman Receives Tang Prize
Hemogenyx Pharmaceuticals plc is pleased to announce that its Chairman, Sir Marc Feldmann, has been awarded the 2020 Tang Prize in Biopharmaceutical Science. The Tang Prize in Biopharmaceutical Science recognizes original biopharmaceutical or biomedical research that has led to significant advances towards preventing, diagnosing, and/or treating major human diseases to improve human health.
Sir Marc Feldmann has been awarded the Tang Prize for the development of cytokine-targeting biological therapies for the treatment of inflammatory diseases such as rheumatoid arthritis ("RA"). He was the first to demonstrate that diseased joints in patients suffering from RA have far more tumor necrosis factor ("TNF"), a pro-inflammatory cytokine, than normal. He went on to study the mechanisms of RA and proposed to target TNF for treating RA. He demonstrated that blocking TNF with a specific antibody reduced the inflammation in a mouse model of the disease, opening a path to the development of an anti-TNF antibody for the treatment of RA. Today, anti-TNF antibodies have become a standard therapy for treating RA and a multitude of inflammatory and autoimmune diseases.
For further information on the Tang Prize, please follow this link:
https://www.tang-prize.org/en/first.php
Upon learning of the honour, Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are thrilled that Sir Marc's transformative work has been recognized by this prestigious prize and we are fortunate to have such a distinguished scientist as our Chairman and advising the Company on its cutting edge cancer and autoimmune disease research and development."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation No 596/2014 until the release of this announcement.
The Directors considered that AbpHC, in addition to their use for disease modelling and drug testing, could potentially be used as a tool for the rapid discovery of human antibodies against human specific viral pathogens
Love it
Eviking.i first purchased at 10p and have invested thousands on the way down to 6p hoping to find the bottom.im personally not bothered about my current investment in hemo due to globico adding an extension and orgenisis realising information about there collab with hemo who "has a very unique product" as told in there presentation.
I believe imo that we will see 9p plus coming up to the globico time frame for the next update due to Fomo,I'm going to keep topping up until I get to my 500k holding and then wait for updates to roll in.just remember hemo Isnt a one trick pony & there future looks bright so believe in your investment and remember what Warren buffet said.
Strong hold imo
CEO tweet just landed
For all who follow me: All tweets and opinions are mine only and are not connected with the business of ANY enterprise. Please, follow official announcements via RNS ON THE LSE. Those are the ONLY reliable source of information about any company you may be interested in.
Have Youse seen this
https://twitter.com/tom2oo9/status/1268226553864949765?s=19
Casper retweeted it
Buy and hold.i will make another small top up at 8p tomorrow.lower my average and I can see this being 9p plus by Wednesday so no drama.im surprised a Rns wasnt issued after orgenesis mentioning us numerous times over the past few weeks.
You would think after watching the shares drop from 11p plus down to 5p the ceo would release a interview about the future of the coming to try build momentum and tone...you say you reached your 5p target when its 5.50 ??? That's not 5p its 5.5p